Clinical Trial Update: Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Phase 3 study comparing safety and efficacy of the rituximab biosimilar BCD-020 to MabThera (rituximab) in rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• BCD-020 (rituximab biosimilar)
• MabThera (rituximab)

Snippet

Sponsor: Biocad | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED